Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alvotech (ALVO) Asset Writedowns and Impairment (2021 - 2025)

Historic Asset Writedowns and Impairment for Alvotech (ALVO) over the last 5 years, with Q3 2025 value amounting to $3.5 million.

  • Alvotech's Asset Writedowns and Impairment rose 205.58% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 873.18%. This contributed to the annual value of $1.8 million for FY2023, which is 3571.43% down from last year.
  • Alvotech's Asset Writedowns and Impairment amounted to $3.5 million in Q3 2025, which was up 205.58% from $10.6 million recorded in Q2 2025.
  • Over the past 5 years, Alvotech's Asset Writedowns and Impairment peaked at $10.6 million during Q2 2025, and registered a low of -$5.4 million during Q1 2024.
  • Its 5-year average for Asset Writedowns and Impairment is $871916.7, with a median of $62000.0 in 2021.
  • As far as peak fluctuations go, Alvotech's Asset Writedowns and Impairment soared by 2373142.86% in 2023, and later plummeted by 14175.76% in 2024.
  • Alvotech's Asset Writedowns and Impairment (Quarter) stood at -$63000.0 in 2021, then soared by 155.56% to $35000.0 in 2022, then skyrocketed by 23731.43% to $8.3 million in 2023, then crashed by 141.76% to -$3.5 million in 2024, then skyrocketed by 199.77% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q3 2025, $10.6 million for Q2 2025, and -$5.4 million during Q1 2025.